|
Video: What is a Stock Split?
|
|
X4 PHARMACEUTICALS is a biopharmaceutical company. Co.'s primary clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor C-X-C receptor type 4, that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, mavorixafor has the potential to provide therapeutic benefit across a variety of neutropenic disorders, including Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome, a rare, primary immunodeficiency. Co. is also developing mavorixafor in a Phase 2 clinical trial in people with certain neutropenic disorders. According to our X4 Pharmaceuticals stock split history records, X4 Pharmaceuticals has had 1 split. | |
|
X4 Pharmaceuticals (XFOR) has 1 split in our X4 Pharmaceuticals stock split history database. The split for XFOR took place on March 14, 2019. This was a 1 for 6 reverse split, meaning for each 6 shares of XFOR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.
When a company such as X4 Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the X4 Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into X4 Pharmaceuticals shares, starting with a $10,000 purchase of XFOR, presented on a split-history-adjusted basis factoring in the complete X4 Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/17/2017 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$83.58 |
|
End price/share: |
$1.17 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.61% |
|
Average Annual Total Return: |
-48.49% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$139.40 |
|
Years: |
6.44 |
|
|
|
Date |
Ratio |
03/14/2019 | 1 for 6 |
|
|